Compare Incyte Corporation (INCY) vs Keysight Technologies Inc (KEYS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs Keysight Technologies Inc — how do they compare? Incyte Corporation trades at $120.64 (market cap $24.54B), while Keysight Technologies Inc trades at $354.44 (market cap $58.74B). The key difference: Keysight Technologies Inc is far larger — about 2.4× Incyte Corporation's market cap, and Keysight Technologies Inc is trading nearer its 52-week high, Incyte Corporation nearer its low. Which is the better fit depends on your goals.
| INCY | KEYS | |
|---|---|---|
Market Cap | $24.54B | $58.74B |
Sector | Health | Technology |
52-Week High | $129.93 | $373.34 |
52-Week Low | $81.61 | $158.51 |
Enterprise Value | $20.04B | $59.08B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Incyte Corporation (INCY) trades at $120.93, down 0.51% on the day, near its 52-week high. The stock shows strong fundamental momentum with Q2 2026 EPS beating estimates at $3.09 versus $2.15 expected, driven by robust Jakafi and Opzelura sales. Revenue growth accelerated to $5.14 billion in 2025, with net income margin expanding to 27.71%. Technical indicators signal a bullish trend with moving averages supporting upside, while oscillators remain neutral.
Outlook remains positive given raised 2026 revenue guidance and recent EU approval for Opzelura, though risks include competitive pressures and reliance on key products. Analyst consensus is bullish with a $122.82 price target, implying modest upside from current levels amid solid institutional ownership trends.
Keysight Technologies (KEYS) trades at $353.23, up 5.31% over the past day and showing strong momentum. The stock is in a bullish technical trend, with recent earnings consistently beating estimates. Revenue for 2025 was $5.38 billion, with a net income margin of 17.31%, and the company has announced strategic collaborations and product launches in 2026, including advancements in 5G and photonics design.
The outlook for KEYS is positive, supported by robust earnings performance and analyst optimism, with an average price target of $396.56. Key risks include high valuation multiples and significant capital expenditure trends. Upside potential hinges on continued execution and market adoption of new technologies.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About Keysight Technologies Inc
Keysight Technologies is a leader in the field of testing and measurement, helping electronics OEMs and suppliers alike bring products to market to fit industry standards and specifications. Keysight specializes in the communications market, but also supplies into the government, automotive, industrial, and semiconductor manufacturing markets. Keysight's solutions include testing tools, analytical software, and services. The firm's stated objective is to reduce time to market and improve efficiency at its more than 30,000 customers.
Read more on KEYS →
